ACT Genomics partners with ASLAN Pharmaceuticals in biomarker exploration for Varlitinib

2017-11-01

ACT Genomics officially launched collaboration with ASLAN Pharmaceuticals as the biomarker exploration partner for Varlitinib in Australia, Hong Kong, Hungary, Japan, Malaysia, Poland, Singapore, South Korea, Spain, Taiwan, Thailand and United States. ASLAN began a global pivotal trial to investigate Varlitinib as a treatment for gastric cancer, biliary tract cancer, and metastatic colorectal cancer. Currently, there is no approved therapies for biliary tract cancer. ASLAN Pharmaceuticals is a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumor types.


More on ASLAN: http://aslanpharma.com/

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草